Progress in the treatment of early-stage inflammatory joint disease

Pfizer has announced that the European Commission has granted a licence extension for Enbrel (etanercept) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Rheumatology early-stage inflammatory joint disease enbrel etanercept Featured Articles pfizer Source Type: news